市場調查報告書
商品編碼
390806

全球生物模擬市場:各應用領域、地區 - 成長,趨勢,預測(2018年∼2023年)

Biosimulation Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 100 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球生物模擬市場,從2018年到2023年的調查期間預計記錄15.9%的年複合成長率。各地區,北美成為這個市場最大的地區。

本報告提供全球生物模擬市場調查,市場概要,各應用領域、地區的市場趨勢,市場規模的變化與預測,市場佔有率,市場促進、阻礙因素以及市場機會、課題分析,競爭情形,主要企業的簡介等系統性資訊。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第6章 成長要素,阻礙因素,機會,課題分析(DROC)

  • 市場成長要素
    • 藥物研發、開發降低成本的必要性
    • 高度的生物模擬工具的必要性
    • 臨床試驗的失敗
    • 由於每人所得上升使醫療支出增加
    • 臨床實驗前的生物模擬的預測準確度的提高
  • 市場阻礙因素
    • 醫護人員的認識不足
    • 標準化流程的缺乏
    • 能處理軟體的技術人員的不足
  • 市場機會
  • 主要課題

第7章 生物模擬市場:各市場區隔

  • 各應用領域
    • 藥物研發
    • 醫藥品開發
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第8章 競爭情形

  • 合併、收購分析
  • 協定,合作,夥伴關係
  • 新產品的銷售

第9章 主要企業

  • Rhenovia Pharma
  • Accelrys
  • Certara
  • Genedata
  • Leadscope
  • Compugen
  • Archimedes
  • Simulations Plus, Inc.
  • Schrodinger Inc.
  • Insilico BioTechnology

第10章 市場未來展望

目錄
Product Code: 55332

Development of a new drug involves considerable amount of research and resources. The process of drug development, from clinical trials to approval, every stage has a very high chance of failure. These chances can be significantly reduced by biosimulation. Biosimulation not only helps in predicting the chances of failure of a drug in the development process, but also reduces the cost of any other possible failures by shrinking the set of clinical experiments. Pharmaceutical giants (such as Pfizer, Merck, Novartis, etc.) and research firms (such as Johnson Pharmaceutical Research & Development) have been employing services offered by biosimulation software and service-providing companies to reduce the trial's duration and the high-cost involved with failures. High drug discovery and development cost is expected to drive this market with a high growth rate for years to come.

The other factors supporting the growth of the market is increasing healthcare expenditure along with technological advancements in the field of biosimulation.

Key Market Trends

Software Segment is Expected to Show Better Growth Over the Forecast Period

Based on the product, it is segmented into software and services. The high growth in the segment is attributed to the growing adoption of biosimulation software by pharmaceutical and research organizations and the increasing R&D investment for pharmaceutical research. Phoenix, which is the industry's premier modeling and simulation software developed by Certara, is used by over 6,000 scientists in 60 countries at nearly 2,000 institutions, including the top 50 global pharmaceutical companies, academic institutes, and research foundations. The software majorly helps in understanding how the body reacts to a drug. Hence, the rising demand for advanced technologies to reduce the cost incurred on drug discovery and development is expected to drive the market.

North America Holds the Largest Share in the Biosimulation Market

The biosimulation market holds the largest share in the North America region. The United States has a considerable number of patients in every disease category, which is the prime reason for pharmaceutical companies to conduct clinical trials for a new drug in this region. Furthermore, companies involved in the business of delivering biosimulation software and services are expanding their scope in drug discovery and drug development by utilizing advanced tools and better software optimization. Hence, considering all these factors, the biosimulation market is expected to grow in the forecast period.

Competitive Landscape

The global players into the biosimulation market are Biovia, Certara, L.P, Compugen Inc., Genedata, In Silico Biosciences, Inc., Leadscope Inc, Pharmaceutical Product Development, LLC, Schrodinger, LLC and Simulations Plus, Inc.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Healthcare Expenditure
    • 4.2.2 Growing Adoption of Biosimulation Software
    • 4.2.3 High Drug Discovery and Development Costs
  • 4.3 Market Restraints
    • 4.3.1 Lack of Awareness Among Healthcare Professionals
    • 4.3.2 Lack of Skilled Personnel
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product
    • 5.1.1 Software
    • 5.1.2 Services
  • 5.2 By Application
    • 5.2.1 Preclinical and Clinical Drug Development
    • 5.2.2 Drug Discovery
    • 5.2.3 Others
  • 5.3 By End User
    • 5.3.1 Pharmaceutical and Biotechnology Companies
    • 5.3.2 Contract Research Organizations
    • 5.3.3 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Biovia
    • 6.1.2 Certara, L.P.
    • 6.1.3 Compugen Inc.
    • 6.1.4 Genedata
    • 6.1.5 In Silico Biosciences, Inc.
    • 6.1.6 Leadscope Inc
    • 6.1.7 Pharmaceutical Product Development, LLC
    • 6.1.8 Schrodinger, LLC
    • 6.1.9 Simulations Plus, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS